{"component": "definition", "props": {"groups": [{"samples": [{"hash": "eD5LjD1UoW5", "uri": "/contracts/eD5LjD1UoW5#indication", "label": "Acquisition and Strategic Collaboration Agreement (Salarius Pharmaceuticals, Inc.)", "score": 33.0328559875, "published": true}, {"hash": "9m7ph8xgnbN", "uri": "/contracts/9m7ph8xgnbN#indication", "label": "Collaboration and License Agreement (Epizyme, Inc.)", "score": 32.1457901001, "published": true}, {"hash": "lmSaGG2GbaE", "uri": "/contracts/lmSaGG2GbaE#indication", "label": "Distribution Agreement", "score": 31.3408622742, "published": true}], "size": 203, "snippet": "means any human disease or condition, or sign or symptom of a human disease or condition.", "snippet_links": [], "hash": "33f13de547a3e98ab21de44b70357b15", "id": 1}, {"samples": [{"hash": "KyCgt2EA1q", "uri": "/contracts/KyCgt2EA1q#indication", "label": "License Agreement (Tonix Pharmaceuticals Holding Corp.)", "score": 32.3538665771, "published": true}, {"hash": "f03N6W5ejAy", "uri": "/contracts/f03N6W5ejAy#indication", "label": "License Agreement (Virpax Pharmaceuticals, Inc.)", "score": 31.8856945038, "published": true}, {"hash": "50L8SYg9nHb", "uri": "/contracts/50L8SYg9nHb#indication", "label": "License Agreement (Provention Bio, Inc.)", "score": 29.3504447937, "published": true}], "size": 49, "snippet": "means a separate and distinct disease or medical condition in humans: (a) which a Product is intended to treat or prevent, as evidenced by the protocol for a clinical trial of such Product or by the proposed Product labeling in an NDA filed with a Regulatory Authority for such Product; or (b) which is contained in a Product\u2019s labeling approved by a Regulatory Authority as part of the Marketing Approval for such Product.", "snippet_links": [{"key": "separate-and-distinct", "type": "clause", "offset": [8, 29]}, {"key": "medical-condition", "type": "definition", "offset": [41, 58]}, {"key": "the-protocol", "type": "clause", "offset": [139, 151]}, {"key": "clinical-trial", "type": "clause", "offset": [158, 172]}, {"key": "product-labeling", "type": "clause", "offset": [208, 224]}, {"key": "regulatory-authority", "type": "definition", "offset": [248, 268]}, {"key": "contained-in", "type": "definition", "offset": [303, 315]}, {"key": "approved-by", "type": "clause", "offset": [337, 348]}, {"key": "marketing-approval", "type": "clause", "offset": [387, 405]}], "hash": "1a23ba02f3e09c14a15c860ad87ac53d", "id": 2}, {"samples": [{"hash": "f6iCUW6ahoB", "uri": "/contracts/f6iCUW6ahoB#indication", "label": "Collaboration, License and Development Agreement (Ionis Pharmaceuticals Inc)", "score": 36.5756340027, "published": true}, {"hash": "7hMGGkEsXt0", "uri": "/contracts/7hMGGkEsXt0#indication", "label": "Strategic Collaboration Agreement (Ionis Pharmaceuticals Inc)", "score": 36.5756340027, "published": true}, {"hash": "iNpxxyOjC9H", "uri": "/contracts/iNpxxyOjC9H#indication", "label": "License Agreement (Monte Rosa Therapeutics, Inc.)", "score": 36.2142372131, "published": true}], "size": 46, "snippet": "means [***].", "snippet_links": [], "hash": "42145ccc68badf480a8ed917c57dd5fc", "id": 3}, {"samples": [{"hash": "56BHgeZoFjA", "uri": "https://www.unthsc.edu/students/wp-content/uploads/sites/26/2021-203104-1-Certificate.pdf", "label": "www.unthsc.edu", "score": 16.1570243835, "published": false}, {"hash": "cXct9fM01zD", "uri": "https://myahpcare.com/wp-content/uploads/2022-203104-1_UNT_DOM_Bro.pdf", "label": "myahpcare.com", "score": 11.283367157, "published": false}, {"hash": "hHhnnx9yXR7", "uri": "https://myahpcare.com/wp-content/uploads/2022-2023_UNT_Certificate.pdf", "label": "myahpcare.com", "score": 11.283367157, "published": false}], "size": 33, "snippet": "means any symptom, cause, or occurrence in a Sickness that points out the cause, diagnosis, course of treatment, or prognosis of the Sickness.", "snippet_links": [{"key": "course-of-treatment", "type": "clause", "offset": [92, 111]}], "hash": "ec61952747de189397a44c01b1348069", "id": 4}, {"samples": [{"hash": "6wdx5m0F7w6", "uri": "/contracts/6wdx5m0F7w6#indication", "label": "License and Collaboration Agreement", "score": 31.3408622742, "published": true}, {"hash": "3eY9s4ns64l", "uri": "/contracts/3eY9s4ns64l#indication", "label": "License and Collaboration Agreement", "score": 31.3408622742, "published": true}, {"hash": "eCbXvMYhqMP", "uri": "/contracts/eCbXvMYhqMP#indication", "label": "License and Collaboration Agreement (Ziopharm Oncology Inc)", "score": 26.2484607697, "published": true}], "size": 28, "snippet": "means a generally acknowledged disease or condition, a significant manifestation of a disease or condition, or symptoms associated with a disease or condition or a risk for a disease or condition. For the avoidance of doubt, all variants of a single disease or condition (e.g., variants of colon cancer or variants of prostate cancer), whether classified by severity or otherwise, shall be treated as the same Indication for purposes of this Agreement.", "snippet_links": [{"key": "associated-with", "type": "definition", "offset": [120, 135]}, {"key": "for-the-avoidance-of-doubt", "type": "clause", "offset": [197, 223]}, {"key": "prostate-cancer", "type": "clause", "offset": [318, 333]}, {"key": "for-purposes-of-this-agreement", "type": "definition", "offset": [421, 451]}], "hash": "0fb8608752d1cdbce272e5e7682a5513", "id": 5}, {"samples": [{"hash": "jtt3AxSwbt", "uri": "/contracts/jtt3AxSwbt#indication", "label": "Contingent Value Rights Agreement (Roche Holdings Inc)", "score": 36.8083496094, "published": true}, {"hash": "7Apt6XK0vrX", "uri": "/contracts/7Apt6XK0vrX#indication", "label": "Merger Agreement (89bio, Inc.)", "score": 36.7125244141, "published": true}, {"hash": "dqFyKRlegh8", "uri": "/contracts/dqFyKRlegh8#indication", "label": "Contingent Value Rights Agreement (Roche Holdings Inc)", "score": 36.0143737793, "published": true}], "size": 27, "snippet": "means a distinct type of human medical disease, disorder or condition.", "snippet_links": [{"key": "type-of", "type": "definition", "offset": [17, 24]}], "hash": "f46be5bc0fbf2edebf9399c21c77c02a", "id": 6}, {"samples": [{"hash": "kD2dgLVVlBK", "uri": "/contracts/kD2dgLVVlBK#indication", "label": "Exclusive License Agreement (Allarity Therapeutics, Inc.)", "score": 33.3723487854, "published": true}, {"hash": "2rLQVGEgVCt", "uri": "/contracts/2rLQVGEgVCt#indication", "label": "Exclusive License Agreement (Allarity Therapeutics, Inc.)", "score": 33.3723487854, "published": true}, {"hash": "8pt8E2gb56L", "uri": "/contracts/8pt8E2gb56L#indication", "label": "Collaboration and License Agreement (Verrica Pharmaceuticals Inc.)", "score": 32.3456535339, "published": true}], "size": 23, "snippet": "means a separately defined, well-categorized class of human disease or condition for which a separate MAA (including any extensions or supplements) is required to be filed with a Regulatory Authority. For clarity, if an MAA is approved for a Product in a particular Indication and patient population, a label expansion for such Product to include such Indication in a different patient population shall not be considered a separate Indication.", "snippet_links": [{"key": "class-of", "type": "definition", "offset": [45, 53]}, {"key": "a-separate", "type": "definition", "offset": [91, 101]}, {"key": "regulatory-authority", "type": "definition", "offset": [179, 199]}, {"key": "for-clarity", "type": "clause", "offset": [201, 212]}, {"key": "patient-population", "type": "clause", "offset": [281, 299]}, {"key": "label-expansion", "type": "definition", "offset": [303, 318]}], "hash": "29a005dc6aca5a1305f1f82d6c89e70f", "id": 7}, {"samples": [{"hash": "edUalaD1oSa", "uri": "/contracts/edUalaD1oSa#indication", "label": "Asset Purchase Agreement (Eliem Therapeutics, Inc.)", "score": 35.4859695435, "published": true}, {"hash": "h2o73Ukdm5W", "uri": "/contracts/h2o73Ukdm5W#indication", "label": "Exclusive License Agreement (CM Life Sciences III Inc.)", "score": 32.8247756958, "published": true}, {"hash": "lmXqpVrFx73", "uri": "/contracts/lmXqpVrFx73#indication", "label": "Discovery Collaboration and License Agreement (Harpoon Therapeutics, Inc.)", "score": 31.1930179596, "published": true}], "size": 22, "snippet": "means each separate and distinct disease, disorder, illness, health condition, or interruption, cessation or disruption of a bodily function, system, tissue type or organ, for which Regulatory Approval is required.", "snippet_links": [{"key": "separate-and-distinct", "type": "clause", "offset": [11, 32]}, {"key": "health-condition", "type": "clause", "offset": [61, 77]}, {"key": "bodily-function", "type": "definition", "offset": [125, 140]}, {"key": "regulatory-approval", "type": "definition", "offset": [182, 201]}], "hash": "7ee08d21fed1170b58c9f183f67c1e15", "id": 8}, {"samples": [{"hash": "1DcXDOYaMK9", "uri": "/contracts/1DcXDOYaMK9#indication", "label": "Collaboration Agreement (Macrogenics Inc)", "score": 24.7563304901, "published": true}, {"hash": "kDZYo4wEeh4", "uri": "/contracts/kDZYo4wEeh4#indication", "label": "Collaboration Agreement (Macrogenics Inc)", "score": 24.6741962433, "published": true}, {"hash": "1NLdooRbXR", "uri": "/contracts/1NLdooRbXR#indication", "label": "Collaboration Agreement (Macrogenics Inc)", "score": 24.5838470459, "published": true}], "size": 21, "snippet": "means a separate and distinct disease, disorder or medical condition in humans or non-human animals which a product is intended to treat, prevent, diagnose, monitor or ameliorate and which, for a Product, is intended to be reflected in the labeling for such Product as an approved Indication, and which, for an approved Product, is reflected in the labeling for such Product.", "snippet_links": [{"key": "separate-and-distinct", "type": "clause", "offset": [8, 29]}, {"key": "medical-condition", "type": "definition", "offset": [51, 68]}, {"key": "approved-indication", "type": "definition", "offset": [272, 291]}, {"key": "approved-product", "type": "definition", "offset": [311, 327]}], "hash": "1a162402211949174c02128f548408f2", "id": 9}, {"samples": [{"hash": "bN0uNdaaAoT", "uri": "/contracts/bN0uNdaaAoT#indication", "label": "License Agreement (Myovant Sciences Ltd.)", "score": 31.376455307, "published": true}, {"hash": "3KlHyQRcRop", "uri": "/contracts/3KlHyQRcRop#indication", "label": "License Agreement (Myovant Sciences Ltd.)", "score": 27.8145103455, "published": true}, {"hash": "7bxdPJmyvpH", "uri": "/contracts/7bxdPJmyvpH#indication", "label": "License Agreement (Myovant Sciences Ltd.)", "score": 27.8008213043, "published": true}], "size": 19, "snippet": "means the use of a Licensed Product for the treatment, prevention, cure, or control of a specific human disease, disorder, illness, or condition.", "snippet_links": [{"key": "licensed-product", "type": "clause", "offset": [19, 35]}, {"key": "control-of", "type": "definition", "offset": [76, 86]}], "hash": "1967d0d8de1354257c16b27b19dbd8a6", "id": 10}], "next_curs": "ClcSUWoVc35sYXdpbnNpZGVyY29udHJhY3RzcjMLEhpEZWZpbml0aW9uU25pcHBldEdyb3VwX3Y1NiITaW5kaWNhdGlvbiMwMDAwMDAwYQyiAQJlbhgAIAA=", "definition": {"size": 2422, "snippet": "means any human disease or condition, or sign or symptom of a human disease or condition.", "title": "Indication", "id": "indication", "examples": ["<strong>Indication</strong> of the Purchaser\u2019s ownership of a Receivable shall be deleted from or modified on the Seller\u2019s computer systems when, and only when, the Receivable shall have been paid in full or repurchased.", "<strong>Indication</strong> of the Purchaser\u2019s and the Collateral Agent\u2019s interest in a Receivable shall be deleted from or modified on the Servicer\u2019s computer systems when, and only when, the related Receivable shall have been paid in full or repurchased.", "Zenas shall use Commercially Reasonable Efforts to Commercialize: (a) at least [***] for [***] Orelabrutinib Products, (b) at least [***] for [***] IL-17 Products, and (c) at least [***] for [***] TYK2 Product, in each case ((a), (b) and (c)), in the Licensed Field and [***]; provided, that Zenas has obtained the Regulatory Approvals to Commercialize such Licensed Product for such <strong>Indication</strong> in such country.", "<strong>Indication</strong> of Borrower Ownership; Inspection and Release of Custodian Files.", "Unless otherwise agreed by the Parties in writing, neither Party shall actively promote, market, or sell the Licensed Product for any <strong>Indication</strong> outside of its respective Field.", "If either Party receives any order for any Licensed Product from a prospective purchaser reasonably believed to be located in a country in the other Party\u2019s Respective Territory or for an <strong>Indication</strong> that belongs to the other Party\u2019s Field, such Party shall promptly refer that order to the other Party and such Party shall not accept any such orders."], "related": [["first-indication", "First Indication", "First <strong>Indication</strong>"], ["competing-product", "Competing Product", "Competing Product"], ["second-indication", "Second Indication", "Second <strong>Indication</strong>"], ["diagnostic-product", "Diagnostic Product", "Diagnostic Product"], ["reference-biological-product", "Reference biological product", "Reference biological product"]], "related_snippets": [], "updated": "2026-04-02T05:49:26+00:00"}, "json": true, "cursor": ""}}